- Home
- VINP vs EYPT Comparison
VINP vs EYPT Comparison
Compare VINP & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- EYPT
- Stock Information
- Founded
- VINP 2009
- EYPT 1987
- Country
- VINP Brazil
- EYPT United States
- Employees
- VINP N/A
- EYPT N/A
- Industry
- VINP Investment Managers
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- VINP Finance
- EYPT Industrials
- Exchange
- VINP Nasdaq
- EYPT Nasdaq
- Market Cap
- VINP 641.7M
- EYPT 594.5M
- IPO Year
- VINP 2021
- EYPT 2005
- Fundamental
- Price
- VINP $10.15
- EYPT $8.47
- Analyst Decision
- VINP Strong Buy
- EYPT Strong Buy
- Analyst Count
- VINP 2
- EYPT 8
- Target Price
- VINP $13.50
- EYPT $25.71
- AVG Volume (30 Days)
- VINP 73.2K
- EYPT 913.4K
- Earning Date
- VINP 02-05-2025
- EYPT 03-06-2025
- Dividend Yield
- VINP 6.28%
- EYPT N/A
- EPS Growth
- VINP N/A
- EYPT N/A
- EPS
- VINP 0.60
- EYPT N/A
- Revenue
- VINP $88,217,697.00
- EYPT $45,713,000.00
- Revenue This Year
- VINP $17.23
- EYPT N/A
- Revenue Next Year
- VINP $51.06
- EYPT N/A
- P/E Ratio
- VINP $16.71
- EYPT N/A
- Revenue Growth
- VINP 9.03
- EYPT 7.50
- 52 Week Low
- VINP $9.01
- EYPT $6.90
- 52 Week High
- VINP $11.85
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- VINP 53.40
- EYPT 55.31
- Support Level
- VINP $9.61
- EYPT $7.15
- Resistance Level
- VINP $10.25
- EYPT $9.08
- Average True Range (ATR)
- VINP 0.23
- EYPT 0.66
- MACD
- VINP 0.07
- EYPT 0.14
- Stochastic Oscillator
- VINP 80.34
- EYPT 64.68
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.